Cross-sectional study on neuropathic pain in cancer patients

Cross-sectional study on neuropathic pain in cancer patients - Cross-sectional study on neuropathic pain in cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054421

Enrollment

1000

Registered

2024-05-20

Start date

2024-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain in cancer patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have been notified of their cancer and whose stage is II or higher 2) Patients who are 18 years of age or older at the time consent is obtained. 3) Patients who are able to understand the procedures of this study, are able to respond appropriately to questions in Japanese without assistance, and are able to give their free and voluntary consent to participate in the study.

Exclusion criteria

Exclusion criteria: No setting in this study

Design outcomes

Primary

Measure	Time frame
The proportion of patients with possible neuropathic pain.	—

Secondary

Measure	Time frame
Location of pain, NRS of pain, where to consult for pain, communication with health care providers, impact on life, percentage of patients with possible neuropathic pain by cancer type Percentage of patients with possible neuropathic pain by stage Breakdown of analgesics used and satisfaction with each of them EQ-5D-5L (quality of life score) Percentage of patients scoring 9 or higher on S-LANSS (overall, cancer type, stage)	—

Measure

Time frame

Location of pain, NRS of pain, where to consult for pain, communication with health care providers, impact on life, percentage of patients with possible neuropathic pain by cancer type Percentage of patients with possible neuropathic pain by stage Breakdown of analgesics used and satisfaction with each of them EQ-5D-5L (quality of life score) Percentage of patients scoring 9 or higher on S-LANSS (overall, cancer type, stage)

—

Countries

Japan

Contacts

Public ContactHaruhiko Seki

INTAGE Healthcare Inc. Value & Access Department

haruhiko.seki@intage.com03-5295-1579

Outcome results